The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD + AML but retains in vitro sensitivity to PKC412 and Sunitinib

Leukemia

Volumn 27, Issue 6, 2013, Pages 1416-1418

  Albers, C ^a   Leischner, H ^a,c   Verbeek, M ^a   Yu, C ^a   Illert, A L ^b   Peschel, C ^a   Von Bubnoff, N ^b   Duyster, J ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFARABINE; CYTARABINE; FLT3 ITD PROTEIN; HYBRID PROTEIN; LEUKOCYTE ANTIGEN; MIDOSTAURIN; MITOXANTRONE; QUIZARTINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CASE REPORT; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG TOLERANCE; FEMALE; GENE DUPLICATION; GENE MUTATION; GENE SEQUENCE; HUMAN; IN VITRO STUDY; KARYOTYPE; LETTER; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; PRIORITY JOURNAL; SALVAGE THERAPY;

ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; DRUG RESISTANCE, NEOPLASM; FMS-LIKE TYROSINE KINASE 3; HUMANS; INDOLES; MUTATION; PHENYLUREA COMPOUNDS; PYRROLES; STAUROSPORINE;

EID: 84878916655     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.14     Document Type: Letter

References (8)

1. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009; 114: 2984-2992.
2. von Bubnoff N, Engh RA, Aberg E, Sanger J, Peschel C, Duyster J. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro. Cancer Res 2009; 69: 3032-3041.
3. von Bubnoff N, Rummelt C, Menzel H, Sigl M, Peschel C, Duyster J. Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib. Leukemia 2010; 24: 1523-1525.
4. Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004; 64: 6385-6389. (Pubitemid 39297890)
5. Heidel F, Solem FK, Breitenbuecher F, Lipka DB, Kasper S, Thiede MH et al. Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2006; 107: 293-300. (Pubitemid 43053554)
6. Kancha RK, Grundler R, Peschel C, Duyster J. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations. Exp Hematol 2007; 35: 1522-1526. (Pubitemid 47419140)
7. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012; 485: 260-263.
8. Moore AS, Faisal A, de Castro DG, Bavetsias V, Sun C, Atrash B et al. Selective FLT3 inhibition of FLT3-ITD() acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Leukemia 2012; 26: 1462-1470.